Strategies for Improving ERBB2 (HER2) Testing in NSCLC Within Community Settings - CME

CME

Title: Strategies for Improving ERBB2 (HER2) Testing in NSCLC Within Community Settings

Link

Description: The pace at which targetable tumor-specific molecular alterations have been identified over the past decade have ushered in an era of precision oncology, yielding significant insights into the diversity of cancer, offering diagnostic and prognostic benefits, and guiding therapy selection. Indeed, guidelines emphasize that comprehensive biomarker testing should be conducted to identify actionable mutations in non-small-cell lung cancer (NSCLC), including ALK, EGFR, KRAS, MET, RET, and ERBB2 (HER2). These tests guide the selection of targeted therapies that can inhibit oncogenic pathways directly implicated in tumor growth and progression. However, comprehensive molecular testing continues to be underused, especially in community hospital settings. Underlying reasons are many and varied, and include lack of clinical knowledge, lack of multidisciplinary support in the interpretation of test results, shortcomings in tissue samples, lack of access to tests, reimbursement challenges, and turnaround times. Quality improvement (QI) programs are well suited to facilitate adoption of system-level solutions to improve guideline recommended testing of patients with NSCLC, including in patients with HER2 (ERBB2) mutations; To improve guideline recommended testing of patients with NSCLC, including in patients with HER2 (ERBB2) mutations, implementation-focused educational programs facilitating system- and process-related changes along with formalized training cascades are key to mitigating barriers. This interactive practice guide offers interventions for both team training and infrastructure building in a cost effective and high impact way. Learners can identify solutions most relevant to their scope of practice and areas of need. Don’t delay! Start improving your NSCLC biomarker testing to optimize treatment processes and practices now!

Target Audience: This activity is intended for multidisciplinary providers treating patients with NSCLC in the community cancer setting including thoracic oncologists, thoracic surgeons, medical oncologists, molecular pathologists, pulmonologists, oncology pharmacists, clinical pharmacists, patient navigators, tissue navigators, and other members of the multidisciplinary team.

Learning Objectives

Assess current NSCLC biomarker testing practices to confirm compliance with the latest guideline recommendations for a broad multi-panel approach
Develop strategies to mitigate challenges and barriers to standardizing ERBB2 (HER2) testing in all patients with advanced NSCLC
Establish multidisciplinary frameworks to interpret biomarker test findings prior to initiating first-line treatment and reassess again when initiating second-line treatment

Estimated Duration: 150 minutes

Delivery Mode: Online

Format: Online Learning

Specialties: Oncology, Pulmonology, Thoracic Surgery

Disclosures and Disclaimers: The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s). This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and The University of Chicago require the speaker to disclose that a product is not labeled for the use under discussion.

Accredited Providers

The University of Chicago Pritzker School of Medicine
Academy for Continued Healthcare Learning (ACHL)

Commercial Support

Boehringer Ingelheim Pharmaceuticals, Inc

Activity Expiration Date: April 1, 2027

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	2.5 Credits	ACCME- Accreditation Council for Continuing Medical Education